EAST-ASIA PHARMACEUTICAL announced that the company recently received the drug registration certificate for Levofloxacin Tablets issued by the National Medical Products Administration. This drug is a fluoroquinolone antibacterial agent used to treat mild to moderate infections of the respiratory system, urinary system, digestive system, skin and soft tissues, as well as infections in oral, ENT, ophthalmology, and dermatology. As of the announcement date, the main manufacturers in China that have obtained the drug registration certificate include Zhejiang Jingxin Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., and Beijing Jiluohua Pharmaceutical Co., Ltd. The national sales revenue for Levofloxacin Tablets in 2024 is approximately 435 million yuan. The company's acquisition of the drug registration certificate indicates that it is qualified to produce and sell this drug, which will have a positive impact on the company's future development